Shorter DAPT durations provide best balance between efficacy, safety
Short-term (≤6 months) and shorter durations (≤3 months) of dual antiplatelet therapy (DAPT) reduce the risk of bleeding and are equally effective, with a trend towards lower all-cause mortality independent of coronary artery disease stability, according to the results of a meta-analysis.
Shorter DAPT durations provide best balance between efficacy, safety
12 Aug 2021
